Simvastatin therapy in patients with hepatic disease
Aim. To assess effectiveness, safety, and tolerability of simvastatin (Vasilip) in patients with IIa and IIb dyslipidemia, as well as with hepatic disease. Material and methods. The analysis included 30 patients receiving Vasilip (20 mg/d). At baseline and after 3, 6, and 14 months of the treatment,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2007-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1359 |